TME Pharma N.V. (FR:ALTME)
:ALTME
Want to see FR:ALTME full AI Analyst Report?
Top Page
TME Pharma N.V.
(ALTME)
Select Model
Select Model
Rating:45Neutral
Price Target:
€0.09
▲(41.67% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily held down by weak financial performance (minimal revenue, persistent losses, negative equity, and ongoing cash burn with increased debt in 2025). Technicals are modestly supportive with price above shorter-term averages and positive MACD, but still below the 200-day average. Valuation does not provide support because earnings are negative and there is no dividend yield.
Positive Factors
Focused oncology R&D niche
A clear strategic focus on the tumor microenvironment and difficult-to-treat cancers (including brain tumors) aligns the company with durable unmet needs in oncology. This specialization concentrates R&D resources, can create differentiated IP, and targets markets with sustained demand for novel therapies.
Negative Factors
Weakened balance sheet
Negative shareholders’ equity and a sharp increase in absolute debt in 2025 materially raise solvency and financing risks. A shrinking asset base reduces collateral and strategic optionality, making the company more dependent on external capital and less resilient to funding stress over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology R&D niche
A clear strategic focus on the tumor microenvironment and difficult-to-treat cancers (including brain tumors) aligns the company with durable unmet needs in oncology. This specialization concentrates R&D resources, can create differentiated IP, and targets markets with sustained demand for novel therapies.
Read all positive factors
TME Pharma N.V. (ALTME) vs. iShares MSCI France ETF (EWQ)
Market Cap
€7.25M
Dividend YieldN/A
Average Volume (3M)547.76K
Price to Earnings (P/E)―
Beta (1Y)-0.42
Revenue GrowthN/A
EPS Growth82.57%
CountryFR
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,188,980
10 Day Avg. Volume795,319
30 Day Avg. Volume547,758
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
TME Pharma N.V. Business Overview & Revenue Model
Company Description
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipe...
How the Company Makes Money
null...
TME Pharma N.V. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 19.00K | 17.00K | 0.00 | 33.00K |
| Gross Profit | -8.00K | -78.00K | -127.00K | -92.00K | -65.97K |
| EBITDA | -2.90M | -5.25M | -5.07M | -11.63M | -12.88M |
| Net Income | -3.29M | -5.72M | -6.74M | -15.13M | -14.45M |
Balance Sheet | |||||
| Total Assets | 2.14M | 3.41M | 2.49M | 5.24M | 9.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.02M | 3.25M | 2.25M | 4.63M | 9.48M |
| Total Debt | 2.66M | 56.00K | 1.17M | 4.09M | 2.44M |
| Total Liabilities | 3.72M | 1.79M | 2.79M | 6.51M | 5.27M |
| Stockholders Equity | -1.58M | 1.61M | -294.00K | -1.27M | 4.51M |
Cash Flow | |||||
| Free Cash Flow | -3.42M | -4.65M | -5.65M | -12.16M | -12.39M |
| Operating Cash Flow | -3.42M | -4.63M | -5.63M | -12.14M | -12.38M |
| Investing Cash Flow | 8.00K | -21.00K | -19.00K | -21.00K | -14.00K |
| Financing Cash Flow | 2.18M | 5.66M | 3.27M | 7.29M | 11.50M |
TME Pharma N.V. Technical Analysis
Negative
0.06
Price Trends
0.08
Negative
0.08
Positive
0.08
Negative
Market Momentum
>-0.01
Positive
42.58
Neutral
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTME, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.58 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALTME.
TME Pharma N.V. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €150.06M | -2.97 | -658.91% | ― | -77.92% | 11.11% | |
48 Neutral | €208.49M | -3.19 | -634.16% | ― | 291.43% | 12.24% | |
46 Neutral | €1.54B | -60.16 | ― | ― | ― | ― | |
45 Neutral | €7.25M | -2.21 | -876.63% | ― | ― | 82.57% | |
43 Neutral | €194.99M | -4.62 | -30.75% | ― | 32.62% | -7.59% | |
42 Neutral | €81.17M | -2.13 | -52.76% | ― | -96.25% | -197.89% |
* Healthcare Sector Average
FR:ALTME
TME Pharma N.V.
0.08
>-0.01
-6.10%
FR:IPH
Innate Pharma SA
1.60
<0.01
0.57%
FR:NANO
Nanobiotix
30.40
26.52
683.51%
FR:TNG
Transgene
0.75
-0.14
-16.07%
FR:OSE
OSE Immunotherapeutics SA
3.58
-1.36
-27.54%
FR:ALCLS
Cellectis SA
2.70
1.42
111.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.